LLY

715.06

-1.34%↓

JNJ

152.52

-0.44%↓

ABBV

182.34

+0.35%↑

NVO

68.13

-0.07%↓

UNH

296.46

-2.25%↓

LLY

715.06

-1.34%↓

JNJ

152.52

-0.44%↓

ABBV

182.34

+0.35%↑

NVO

68.13

-0.07%↓

UNH

296.46

-2.25%↓

LLY

715.06

-1.34%↓

JNJ

152.52

-0.44%↓

ABBV

182.34

+0.35%↑

NVO

68.13

-0.07%↓

UNH

296.46

-2.25%↓

LLY

715.06

-1.34%↓

JNJ

152.52

-0.44%↓

ABBV

182.34

+0.35%↑

NVO

68.13

-0.07%↓

UNH

296.46

-2.25%↓

LLY

715.06

-1.34%↓

JNJ

152.52

-0.44%↓

ABBV

182.34

+0.35%↑

NVO

68.13

-0.07%↓

UNH

296.46

-2.25%↓

Search

Innoviva Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

18.81 -0.69

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

18.56

Max

19

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-67M

-47M

Pardavimai

-3.2M

89M

P/E

Sektoriaus vid.

51.694

54.533

Pelnas, tenkantis vienai akcijai

-0.743

Pelno marža

-52.559

Darbuotojai

127

EBITDA

-63M

-27M

Rekomendacijos

By TipRanks

Rekomendacijos

Pirkti

12 mėnesių prognozė

+190.24% upside

Dividendai

By Dow Jones

Kitas uždarbis

2025-07-29

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-6.8M

1.2B

Ankstesnė atidarymo kaina

19.5

Ankstesnė uždarymo kaina

18.81

Naujienos nuotaikos

By Acuity

100%

0%

369 / 382 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Strong Bullish Evidence

Innoviva Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-05-22 23:48; UTC

Karštos akcijos

Stocks to Watch: Deckers Outdoor, Intuit, Ross Stores, Lightbridge, NuScale Power, Centrus Energy

2025-05-22 23:07; UTC

Svarbiausios naujienos

Fortescue Energy CEO to Resign in Executive Overhaul

2025-05-22 23:03; UTC

Pagrindinės rinkos jėgos

Nuclear-Industry Stocks Get Boost After Report Says Trump Will Sign Orders to Jumpstart Field

2025-05-22 23:59; UTC

Rinkos pokalbiai

Gold Edges Higher, Supported by Lingering Worries Over U.S. Deficits -- Market Talk

2025-05-22 23:45; UTC

Rinkos pokalbiai

Nikkei May Trade in Range as Uncertainty Over Tariffs Continues -- Market Talk

2025-05-22 23:45; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2025-05-22 23:23; UTC

Rinkos pokalbiai

Global Energy Roundup: Market Talk

2025-05-22 23:23; UTC

Rinkos pokalbiai

Fortescue Iron Bridge Delay Disappoints; Executive Changes Welcomed -- Market Talk

2025-05-22 20:50; UTC

Rinkos pokalbiai

Auto & Transport Roundup: Market Talk

2025-05-22 20:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2025-05-22 20:46; UTC

Įsigijimai, susijungimai, perėmimai

Alcon and Lensar Receive FTC Requests for Additional Information About Merger

2025-05-22 20:39; UTC

Uždarbis

Tesla's Emissions Credits Are at Risk After Senate's California Vote -- Barrons.com

2025-05-22 20:36; UTC

Svarbiausios naujienos

Antitrust Cops Say BlackRock, Other Fund Giants May Have Harmed Energy Competition -- 4th Update

2025-05-22 20:36; UTC

Svarbiausios naujienos
Uždarbis

Workday Logs Higher 1Q Revenue, Backs Outlook; Initiates $1B Buyback Program

2025-05-22 20:32; UTC

Svarbiausios naujienos
Uždarbis

Intuit Stock Rises After Earnings Grew More than Expected In Latest Tax Season -- Barrons.com

2025-05-22 20:27; UTC

Svarbiausios naujienos

Trump's 'Big, Beautiful Bill' Heads to Senate, Where New Fights Loom -- WSJ

2025-05-22 20:20; UTC

Svarbiausios naujienos

Bond Market Shows Signs of Stabilizing; Nasdaq Rises -- WSJ

2025-05-22 20:17; UTC

Svarbiausios naujienos

The Deficit Is Unsettling Bond Traders. Here's How That Affects the Economy. -- 2nd Update

2025-05-22 20:16; UTC

Uždarbis

Intchains Group 1Q Rev $18.2M >ICG

2025-05-22 20:15; UTC

Svarbiausios naujienos

Bond Market Shows Signs of Stabilizing; Nasdaq Rises -- WSJ

2025-05-22 20:08; UTC

Svarbiausios naujienos
Uždarbis

Intuit Stock Rises After Earnings Grew More than Expected In Latest Tax Season -- Barrons.com

2025-05-22 20:05; UTC

Svarbiausios naujienos

Intuit Seeing Stable Environment for Consumers, Businesses While Tariffs Play Out

2025-05-22 20:04; UTC

Uždarbis

Workday Sees FY26 Subscription Revenue $8.8B >WDAY

2025-05-22 20:04; UTC

Uždarbis

Workday Sees 2Q Subscription Revenue $2.16B >WDAY

2025-05-22 20:01; UTC

Uždarbis

Intuit Sees FY25 EPS $13.19-EPS $12.24 >INTU

2025-05-22 20:01; UTC

Uždarbis

Workday 1Q Net $68M >WDAY

2025-05-22 20:01; UTC

Uždarbis

Workday 1Q EPS 25c >WDAY

2025-05-22 20:01; UTC

Uždarbis

Workday 1Q Adj EPS $2.23 >WDAY

2025-05-22 20:01; UTC

Uždarbis

Workday 1Q Subscription Revenue $2.06B >WDAY

2025-05-22 20:01; UTC

Uždarbis

Workday 1Q Rev $2.24B >WDAY

Akcijų palyginimas

Kainos pokytis

Innoviva Inc Prognozė

Kainos tikslas

By TipRanks

190.24% į viršų

12 mėnesių prognozė

Vidutinis 55 USD  190.24%

Aukščiausias 55 USD

Žemiausias 55 USD

Remiantis 1 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Innoviva Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

1 ratings

1

Pirkti

0

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

18.57 / 18.75Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Strong Bullish Evidence

Vidutinės trukmės periodas

Weak Bullish Evidence

Ilgalaikis periodas

Neutral Evidence

Rinkos nuotaikos

By Acuity

369 / 382 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Labai stiprus meškų rinkos įrodymas

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Žemiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Innoviva Inc

Innoviva, Inc. engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company's products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Its development pipeline includes zoliflodacin, a late-stage product candidate, a potential single oral dose cure for the treatment of uncomplicated gonorrhea. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. It has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.